CAJ | 학술논문

近年来跨国药企在中国行贿事件陆续曝光，揭示了其在发展中国家获取高额利润部分依靠权力运作的事实。跨国药企主要是透过制度策略、政商策略与营销策略进行权力运作以打通商业关节。在制度方面，药企游说母国在国际上推动有利于跨国资本流动的国际规范与有利于他们的专利权制度；政商策略表现在跨国企商常与发展中国家政府共谋，并与母国审查人员有利益关联，还促使政府加快药品核准上市的流程等；营销策略则包含扩大药物使用范围及透过行贿控制高药价等，三种策略皆镶嵌在新自由主义全球化的结构力量之中。
근년래과국약기재중국행회사건륙속폭광，게시료기재발전중국가획취고액리윤부분의고권력운작적사실。과국약기주요시투과제도책략、정상책략여영소책략진행권력운작이타통상업관절。재제도방면，약기유설모국재국제상추동유리우과국자본류동적국제규범여유리우타문적전리권제도；정상책략표현재과국기상상여발전중국가정부공모，병여모국심사인원유이익관련，환촉사정부가쾌약품핵준상시적류정등；영소책략칙포함확대약물사용범위급투과행회공제고약개등，삼충책략개양감재신자유주의전구화적결구역량지중。
Recently a couple of multinational pharmaceutical companies （MPC） have been exposed being involved in bribing in China, which enclosed a fact that apart from their products＇ quality, MPCs heavily rely on power operating to guarantee their high profits. However, in China there has been a lack of sociological research on their power maneuvering. It is this research＇s aim to fill in the gap, and it suggests MPCs have made their way through three types of strategies regarding institution, political- commercial relationship and marketing, and all three strategies are embedded in the structure of neoliberal globalization. Institutionally, MPCs lobby their home countries to push forward policies and international norms in favor of cross-border capital flows, and take sides with the patent system to protect private property system in the international community. Politic-commercial relationship-wise, MPCs build up complicity with the governments of developing countries, develop the medical examiners of home countries their stakeholders, and prompt the governments of their own to speed up the listing of approved drugs processes. Marketing strategies include seven ways of doing ranging from expanding the scope of drug use to controlling high prices of medicine through bribery.